Latest news
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sat, 01 Aug 2026 06:33:05 GMTMerck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination - Fierce BiotechFierce Biotech · Wed, 29 Jul 2026 07:00:00 GMTSouth Korea's FDA Sets First Concrete Clinical Trial Exemption Rules for Medical AI, Expands Special Provisions for Generative AI - finance.biggo.comfinance.biggo.com · Tue, 28 Jul 2026 05:56:00 GMT